Abstract
Increased 5α-reductase activity has been found in hair follicles of hirsute women, suggesting a pathogenetic role. The aim of the present study was to evaluate the effect of finasteride in the treatment of idiopathic hirsutism. Twenty-seven women with idiopathic hirsutism, aged 16–35 years, were treated for 6 months with finasteride, 5 mg once daily. Fourteen patients were on finasteride alone (group A), while the remaining received in addition an oral contraceptive (group B). Clinical, hormonal and biochemical evaluation were performed before, and after 3 and 6 months of treatment. Clinical evaluation was repeated 6 months after drug discontinuation in seven patients. Treatment was well tolerated by all patients; no side effects or adverse reactions were reported. A significant improvement of hirsutism was obtained by finasteride; clinical score observed at the 6th month of therapy was reduced from 11.71 ±2.23 to 7.92±1.81 (p<0.05) and from 14.92±6.13 to 9.3±2.75 (p<0.05) in group A and B, respectively. Clinical score in seven patients was still 8.61 ±2.28 (p<0.05) 6 months after the end of therapy. Finasteride treatment alone (group A) induced a slight increase, though not significant, in serum androgens; DHT and SHBG did not change. In group B (finasteride plus oral contraceptive) total testosterone and free testosterone showed no significant decrease; after 6 months of therapy DHT was reduced significantly, while SHBG levels were increased. These data demonstrate that 5α-reductase inhibition may be an effective treatment in women suffering from idiopathic hirsutism. This approach may be attractive due to the absence of adverse reactions, although the necessity of an adequate contraception should be kept in mind.
Similar content being viewed by others
References
Biffignandi P., Massucchetti C., Molinatti G.M. Female hirsutism: pathophysiological consideration and therapeutic implications. Endocr. Rev. 5: 498, 1984.
Erkkola R., Ruutiainen K. Hirsutism: definitions and etiology. Ann. Med. 22: 99, 1990.
Serafini P., Lobo R.A. Increased 5α-reductase activity in idiopathic hirsutism women. J. Clin. Endocrinol. Metab. 43: 74, 1985.
Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., Leblanc G., Durosher F., Paquet N. Structure of human type II 5α-reductase gene. Endocrinology 131: 1571, 1992.
Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russel D.W. Tissue distribution and ontogeny of steroid 5α-reducstase isozyme expression. J. Clin. Invest. 92: 903, 1993.
Wilson J.D., Griffin J.E., Russel D.W. Steroid 5α-reductase 2 deficiency. Endocr. Rev. 14: 577, 1993.
Thigpen A.E., Davis D.L., Gautier T., Imperato McGinley J., Russel DW. Brief Report: the molecular basis of steroid 5α-reductase deficiency in a large dominican kindred. N. Engl. J. Med. 327: 1216, 1992.
Peters D.H., Sorkin E.M. Finasteride. Drugs 46: 177, 1993.
Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21: 1440, 1961.
Carr B.R., Breslau N.A., Givens C., Byrd W., Barnett-Hamm C., Marshburn P.B. Oral contraceptive pills, Gonadotropin-Releasing Hormone Agonist, or use in combination for treatment of hirsutism: a clinical research center study. J. Clin. Endocrinol. Metab. 80: 1169, 1995.
Spritzer P., Billaud L., Thalabard J.C., Birman P., Mowszowicz I., Raux-Demay MC., Clair F., Kuttenn F., Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 70: 642, 1990.
Cusan L., Dupont A., Gomez J.-L., Tremblay R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril. 61: 281, 1994.
O’Brien R.C., Cooper M.E., Murray R.M.L., Seeman E., Thomas A.K., Jerums G. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 72: 1008, 1991.
Nielsen P.G. Treatment of idiopathic hirsutism with spironolactone. Dermatologica 165: 194, 1982.
Jones K.R., Katz M., Keyzer C., Gordon W. Effect of cyproterone acetate on rate of hair growth in hirsute females. Br. J. Dermatol. 105: 685, 1981.
Helfer E.L., Miller J.C., Rose L.I. Side effects of spironolactone therapy in the hirsute women. J. Clin. Endocrinol. Metab. 66: 208, 1988.
Wysowki D.K., Frieman J.P., Tourtelot J.B., Horton M.L. Fatal and non fatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118: 860, 1993.
Wallace C., Lalor E.A., Chik C.L. Hepatotoxicity complicating Flutamide treatment of hirsutism. Ann. Intern. Med. 119: 1150, 1993.
Faloia E., Filipponi S., Mancini V., Morosini P., De Pirro R. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J. Endocrinol. Invest. 16: 675, 1993.
Andreiko J.L., Monroe S.E., Jaffe R.B. Treatment of hirsutism with a gonadotropin-releasing hormon agonist (nafarelin). J. Clin. Endocrinol. Metab. 63: 854, 1986.
Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 67: 701, 1988.
Mellin T.N., Busch R.D., Rasmusson G.H. Azasteroid as inhibitors of testosterone 5α-reductase in mammalian skin. J. Steroid. Biochem. Mol. Biol. 44: 121, 1993.
Dallob A.L., Sadich N.S., Unger W., Lipert S., Geissler L.A., Gregoir S.L., Nguyen H.H., Moore E.C., Tanaka W.K. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J. Clin. Endocrinol. Metab. 79: 703, 1994.
Fruzzetti F., De Lorenzo D., Parrini D., Ricci G. Effect of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 79: 831, 1994.
Wong I.L., Morris R.S., Chang L., Spahn M.A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 80: 233, 1995.
Moghetti P., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., Bellotti G., Muggeo M. Clinical and hormonal effect of the 5α-reductase inhibitor finasteride in hirsutism. J. Clin. Endocrinol. Metab. 79: 1115, 1994.
Toscano V., Horton R. Circulating Dihydrotestosterone may not reflect peripheral formation. J. Clin. Invest. 79: 1653, 1987.
Ciotta L., Cianci A., Calogero A.E., Palumbo M.A., Marietta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 64: 299, 1995.
Tolino A., Petrone A., Sarnacchiaro F., Cirillo D., Ronsini S., Lombardi G., Nappi C. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil. Steril. 66: 61, 1996.
Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal efects during a 1-year course of therapy and 1-year follow-up. Fertil. Steril. 66: 734, 1996.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Faloia, E., Filipponi, S., Mancini, V. et al. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest 21, 694–698 (1998). https://doi.org/10.1007/BF03350800
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350800